Rachel Lutz

The study authors wrote that understanding this phenomena can lead to determining the best therapeutic strategy with DAAs for certain patients.

The investigators measured a 3.5-month period before and after a policy was implemented to preserve hospital resources.

Experts offered their advice on 2 domains, topic identification and ranking of priorities, for pediatric research realms.

Hepatitis B coinfection with COVID-19 did not increase either disease’s severity or increase duration of hospitalization, according to a small study in China.

Inflammatory bowel disease patients were surveyed about their remission or flare-up status, as well as their expectations for a flare-up over the next 2 months.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

HIV care may help enable better treatment for HCV infectious.

C. diff infections have decreased during the ongoing pandemic.

The estimated the prevalence of C diff infections is about 40 in 30,000 for the sickle cell disease group and about 5000 in 11.8 million for the non-sickle cell disease group.

A new health care pathway could be safe to implement in clinical practice.

Female gender, Caucasian race, and older age were all significantly associated with microscopic colitis.

Investigators compared 2 groups, before and after the initiation of a biosimilar program at their hospital.

The longitudinal study included 209 children, one of the largest samples in the world for a study on this topic.

The study observed 50 women taking infliximab, adalimumab, and vedolizumab.

These findings underline the importance of aggressive management to treat IBD and ACS comorbidities to improve outcomes.

Until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care

Prior coronavirus outbreaks help assess the possible psychiatric dangers related to COVID-19.

Authors say comparing mortality rates between the 2 conditions is a threat to public health.

The treatment was no better than standard care.

A majority of patients hospitalized have at least 1 underlying condition and are older.

Endocrinologists make can a difference in COVID-19 by restricting their use of glucocorticoids.  According to an editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, patients treated with glucocorticoids will be at higher risk for coronavirus disease 2019 (COVID-19), the infection caused by the novel coronavirus. 

Two new papers shine a light on additional symptoms that could help clinicians diagnose novel coronavirus.

Ranibizumab was approved for AMD treatment in Korea in 2007, but most supporting trials had been conducted among Caucasian patients.

A review highlights aflibercept’s efficacy in treatment non-responders and points to a couple promising new AMD therapies in development.

New clinical findings go against the advisory of the GOLD 2017 classification.

Metformin use associated with a 58% reduced risk of age-related macular degeneration (AMD) in a case-controlled retrospective study.

Most surveyed comorbid patients reported they required the help of family, friends or caregivers during pneumonia recovery, and needed an average of 28 days of care.

Patients who experienced hypertensive disorders in pregnancy were 80% more likely to develop choroidal neovascular AMD at an early age.

An early-start treat-and-extend regimen produced comparable efficacy with fewer aflibercept injections than regular injections every 8 weeks.

A new meta analysis speculates whether specialists or primary care physicians are the best clinicians to diagnose, treat, and manage COPD.